Rheumatoid arthritis treatment in new class of medicines

rheumatoid arthritis
A new oral treatment alternative for patients with moderate to severe rheumatoid arthritis, will be available on the PBS from 1 October, 2015. Pfizer's Xeljanz (tofacitinib citrate) has been approved to treat adults with moderate to severe active rheumatoid arthritis, who have had an inadequate response to conventional disease-modifying antirheumatic drugs, such as methotrexate. Xeljanz

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Policy keeping PBS spending in check: Medicines Australia
Next Women in the dark about their breast cancer risk